t
On 24 April 2025, Aptamer Group plc announced the publication of a new corporate presentation and investor factsheet, now available on its investor relations website. The company confirmed that no new material information has been disclosed in either of these publications.
| Date | 24 Apr 2025 |
| Time | 07:00:13 |
| Category | Miscellaneous |
| ID | 9448F |
24 April 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
New Corporate Presentation and Investor Factsheet
Aptamer Group plc (AIM: APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, is pleased to announce that it has published a new corporate presentation and investor factsheet. These materials are now available on the investor relations section of the Group's website (https://aptamergroup.com/investors/reports-and-presentations/).
The corporate presentation outlines Aptamer's strategy, operational progress and financial performance, offering a comprehensive overview of the Group's growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.
No new material information has been disclosed in either of these publications.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/